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The aim of the present paper is to critically review the details of the published nutrition
intervention trials, with and without exercise, targeting sarcopenia. Sarcopenia is the loss
of muscle mass, strength and/or performance with age. Since amino acids and energy are
required for muscle synthesis it is possible that nutritional intake influences sarcopenia.
Nutritional studies are challenging to carry out because of the complexity of modulating
dietary intake. It is very difficult to change one nutrient without influencing many others,
which means that many of the published studies are problematic to interpret. The studies
included evaluate whole protein, essential amino acids and β-hydroxyl β-methylbutyrate
(HMB). Whole-protein supplementation failed to show a consistent effect on muscle
mass, strength or function. This can be explained by the variations in study design, compo-
sition of the protein supplement and the failure to monitor voluntary food intake, adherence
and baseline nutritional status. Essential amino-acid supplements showed an inconsistent ef-
fect but there are only two trials that have significant differences in methodology and the
supplement used. The HMB studies are suggestive of a beneficial effect on older adults,
but larger well-controlled studies are required that measure outcomes relevant to sarcopenia,
ideally in sarcopenic populations. The issues of timing and distribution of protein intake,
and increased splanchnic amino-acid sequestration are discussed, and recommendations
for future trials are made.
Sarcopenia: Vitamin D: Protein: Essential amino acid: β-Hydroxyl β-methylbutyrate
Sarcopenia is the loss of muscle mass, strength and/or
performance with age. There is as yet no universally
agreed definition but a number of groups have published
definitions which differ mainly around the exact cut-off
points used for measures of mass, strength and
performance(1–6).
Since a consistent supply of amino acids and energy
are required for muscle protein synthesis, as well as a
number of other nutrients, it is possible that nutritional
intake contributes to the process of sarcopenia(7).
Consequently modifying nutritional intake may also pro-
vide an opportunity to treat sarcopenia.
The process of muscle synthesis and breakdown is
complex and influenced by various internal and external
factors. A comprehensive review can be found at(8). In
particular, from the nutritional perspective, it is accepted
that amino acids have a stimulatory effect on muscle syn-
thesis, especially leucine(9). Thus, protein and amino
acids have been among the first targets for interventions
to combat sarcopenia, alone or in combination with ex-
ercise, and form the majority of nutritional intervention
trials.
The aim of the present paper is to critically review the
details of the published nutrition intervention trials, with
and without exercise, targeting sarcopenia. Nutritional
studies are challenging to carry out because of the com-
plexity of modulating dietary intake. It is very difficult
to change one nutrient without influencing many others,
which means that many of the published studies are
problematic to interpret. Studies were included if the
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outcome measures reported for the interventions in-
cluded muscle mass and at least one measure of muscle
strength or physical performance, even when the popu-
lation studied was not defined as sarcopenic, since
these outcome measures form part of the definition of
sarcopenia.
Whole-protein studies
A recent systematic review(10) identified five protein sup-
plement studies(11–15), which are summarised in Table 1;
Cruz-Jentoft et al. concluded that there was no consistent
effect on muscle mass, strength or function. A closer
examination of the studies reveal why this may be so.
Table 1 shows that the studies are highly variable in a
number of different aspects, including the population
recruited, the duration, whether the intervention was
combined with exercise, supplementing protein and en-
ergy or protein alone, the formulation and precise
content of the supplements, and whether placebo con-
trolled or not. In addition, the methodological quality
as assessed by Cruz-Jentoft et al. varied from a PEDro
score(16) of 4–10 (10 representing the highest quality
score possible), outcomes measured all varied and all
sample sizes were relatively small ranging from fifty-
seven to ninety-eight people(10).
The duration of the interventions ranged from 6 to 18
months, but the results show no advantage to the longer
duration, but this may be explained by other factors.
Tieland et al. suggest that the lack of effect of protein
supplementation with exercise on physical performance
and strength may be due to duration, postulating that
longer than 6 months intervention would be required(14).
Unfortunately the two available longer term studies(11,12)
had significant design weaknesses making it difficult to
deduce whether this hypothesis can be supported. To
further confuse the issue, in another Tieland et al.
study protein supplementation for 6 months without ex-
ercise did improve physical performance but did not
show gains in muscle mass or strength(15). The popula-
tions were also inconsistent, including older adults
(mean age range 68–83 years) who were free living(12–15)
or in residential care(11). Three studies specifically iden-
tified frail or pre-frail people(11,14,15). This means that
the results cannot be combined and they can only be ap-
plied to these specific groups.
The ability to identify the singular effect of protein
with or without exercise is only possible with two studies,
where a four arm design was used (exercise, protein,
both or none)(11,12). Two other studies looked at the ad-
ditive effect of protein on exercise(13,14), and the final
study examined protein supplementation excluding the
effect of exercise(15). Since there is widespread agreement
that exercise can improve both muscle strength and
physical performance, it would be useful to be able to
examine how nutritional supplements enhance these ef-
fects or not. This requires four arm studies, until the opti-
mally effective exercise intervention is described, when
two arm studies could be justified looking at nutrition
in addition to exercise. Nevertheless, two arm studies
examining nutrition only still have value given the diffi-
culties in motivating people to take up exercise. This
lack of consistency in study design means that comparing
or combining results is difficult or impossible and
explains to a certain extent the variability of the results
to date.
Most importantly the protein interventions tested var-
ied considerably. In two trials the protein was delivered
with additional energy and micronutrients(11,12), but
these trials scored lowest in terms of quality on the
PEDro scale. Bunout et al. do not describe the exact con-
tent of the supplement since it was apparently incorpor-
ated into either soup or porridge and it is not stated what
additional nutrients these foods added. The protein con-
tent is relatively low at 13 g/d, but a range of vitamins
and minerals are also included to provide a more com-
plete supplement(12). Bonnefoy et al. also aimed to pro-
vide a nutritionally complete supplement containing
vitamins and minerals in addition to protein and energy.
The quantities of energy and protein appear significant at
1686 kJ and 30 g protein/d, but this is difficult to assess
without measuring usual food intake to enable an esti-
mate of the overall energy and protein content of the
diet(11). The other three trials aimed to examine the effect
of protein only, with no additional energy or micronutri-
ents. Chale et al. specifically chose to use whey protein
due to the high content of essential amino acids (EAA)
in this protein(13). Tieland et al. do not state the source
of protein(14,15). These three studies provide either 30 or
40 g protein/d, significantly increasing protein intake as
shown by an estimation of dietary intake using 3 d diet-
ary diaries.
The measurement of concurrent food intake is a key
design issue in nutritional intervention trials, but is not
always monitored. Since any nutritional supplement
may have an impact on usual food intake it is important
to measure macronutrient intakes. In the case of protein,
an energy deficit will result in a reduction in protein syn-
thesis even with apparent adequate supplies of amino
acids(17). Similarly, if protein intake from the diet is inad-
equate the supplement will simply improve intake rather
than increasing intake above recommended levels. If
positive benefits are found in the supplemented groups,
then it is important to be able to identify the overall nu-
trient intake to enable accurate interpretation of the
results. If food intake is not measured, then it is imposs-
ible to assess what has produced any positive effect, or
explain why no effect is apparent. The two lower quality
studies did not aim to measure usual food intake(11,12);
the other three studies used 3 d diet diaries at least at
the start and end of the study(13–15).
There are a number of recent articles from expert groups
reviewing the recommended protein levels for older adults.
These suggest that protein intakemay need to increase with
age (specifically over 65 years) to 1·0–1·2 g/kg body weight
per d(18,19). These levels are not universally accepted and
there remains significant debate around this issue(20).
Therefore, it is vital that trials testing protein supplemen-
tation need to enable subjects to at least meet these
newly proposed levels, rather than just providing a fixed
amount in the hope protein intake increases appropriately.
M. Hickson2
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Table 1. Details of protein supplementation trials to treat sarcopenia
Reference
(population)
Intervention
(duration)
Total
supplement/d
No./type of
supplements
Volume/
supplements
Energy/
supplements
Protein
/supplements
Extra
nutrients? Masking Placebo Adherence Dietary intake Main results
Bonnefoy
et al.(11)
(residents of
retirement
homes)
(a) Ex + Supp
(b) Con + Supp
(c) Ex + Placebo
(d) Con +
Placebo
(9 months)
30 g protein
1686 kJ
(400 kcal)
Two drinks
10·00 and
16·00
200 ml 843 kJ (200
kcal)
15 g (30 % of
energy); g/kg
bw per d not
given
Yes –
range of
vits and
mins
providing
25 %
RDA
/supp
Attempted
same
opaque
packaging
but products
likely to taste
and look
different
Yes
No protein,
energy, vits or
mins.
Presumably
was artificially
sweetened and
flavoured water
but not stated
54 % at 9
months
counting
unused units
No measure made
but BMI increased
in the supp group
and supp
designed to
increase energy
intake by
approximately 20
%
Supp
significantly
increased MP
at 3 months v.
Con (P = 0·03),
but not at 9
months. Supp
did not
improve MM or
PP v. Con
Bunout et al.
(12) (free-living
elderly
attending
out-patient
clinics)
(a) Ex + Supp
(b) Supp
(c) Ex
(d) Con
(18 months)
13 g protein
1746 kJ
(418 kcal)
Two prepared
as soup or
porridge
(probably
powdered
product but
not stated)
50 g 873 kJ (209
kcal)
(excluding
soup or
porridge
contribution)
6·5 g; g/kg bw
per d not
given
Yes –
range of
vits and
mins
providing
25 %
RDAs
/supp
Not
applicable
No
Supp provision
not randomised
44–49 %
Self-reported
No assessment of
dietary intake and
no change in body
weight or
composition
Supp alone had
no effect on
MM, MS or PP.
Supp did not
show an
additive effect
over Ex
outcome
Chale et al.(13)
(free-living
elderly)
(a) Supp + Ex
(b) Placebo + Ex
(6 months)
40 g whey
protein
1582 kJ
(378 kcal)
Two powder
sachets am
and pm. If
doing Ex
taken after
the session
Not stated 791 kJ (189
kcal)
20 g; g/kg bw
per d not
given
No Numerically
coded
packages
Yes
Iso-energetic
45 g
maltodextrin 1 g
fat; 791 kJ (189
kcal) PABA for
compliance
checking
67 % Urinary
PABA 72 %
returned
packages
3 d diet diary × 2
Protein intake
greater in supp
group and energy
intake the same as
baseline. Showed
voluntary energy
intake decreased
but supp
maintained it
Supp + Ex did
not improve
MM, MS or PP
significantly v.
Con + Ex
Tieland et al.(14)
(Free living
frail or pre-frail
elderly)*
(a) Supp + Ex
(b) Placebo + Ex
(6 months)
30 g protein Two drinks
after
breakfast
and lunch
250 ml Not stated 15 g; 1·3 g/kg
bw per d
0·4 g Ca All drinks
flavoured
vanilla
opaque
packaging
Yes
No protein
same lactose
and Ca
98 % Ticked
calendars
and returned
cartons
3 d diet diary × 3 No
change in energy
intake, protein
increased in supp
group
Supp + Ex
significantly
improved MM
(P = 0·006), but
not MS or PP
v. Placebo + Ex
Tieland et al.(15)
(free-living
frail or prefrail
elderly)*
(a) Supp
(b) Placebo
(6 months)
30 g protein Two drinks
after
breakfast
and lunch
250 ml Not stated 15 g; 1·4 g/kg
bw per d
0·4 g Ca All drinks
flavoured
vanilla
opaque
packaging
Yes
No protein
same lactose
and Ca
92 % Ticked
calendars
and returned
cartons
3 d diet diary × 3
Energy intake
decreased at 24
months, protein
increased in supp
group
PP improved
significantly
with supp (P =
0·02), but not
MM or MS v.
Placebo
Ex, exercise component; con, control; supp, supplement; bw, body weight; PABA, para-aminobenzoic acid; MM, muscle mass; MP, muscle power; MS, muscle strength; PP, physical performance; vits, vitamins;
mins, minerals.
* Registered as two separate two arm studies.
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Only two studies assessed this(14,15) and showed protein
intake increased up to 1·3–1·4 g/kg body weight per d, but
provided inconsistent results in terms of protein supplemen-
tation as mentioned previously.
Adherence is another critical factor in nutritional
interventions. It is well known that nutritional supple-
ments or changes to dietary intake are notoriously diffi-
cult for subjects to follow consistently(21). All studies in
this group reported adherence, but three had relatively
low rates(11–13), suggesting that a lack of adherence
could be the reason for a lack of effect.
Producing a placebo supplement that enables single or
double blinding to limit bias is also extremely difficult,
particularly if a liquid supplement drink is employed.
Some studies have attempted this; one aiming for an en-
ergy and protein-free placebo(11) and another aiming for
an iso-energetic but protein-free placebo(13). Both these
placebos are likely to taste and feel very different to the
supplement, resulting in unsuccessful masking, at least
to the individuals taking it. Other studies either did not
attempt to provide a placebo(12) or provided limited in-
formation regarding energy content(14,15). None of the
researchers have attempted to test whether masking
was successful, but have simply obscured the liquids
from view to avoid comparison or visual assessment of
the drink. Chale et al. donot provide details of how the sup-
plement powder is consumed; whether added to solid food
or mixed with liquid to produce a drink. In all cases there
is a significant risk that the placebo drink or powder will
be readily identifiable to those consuming it, thus allowing
potential bias to influence results.
Baseline nutrient status is similarly critical to assess.
People who are deficient in any particular nutrient may
respond differently to the given supplement. Vitamin D
status provides a good example of how a deficient status
may influence the effect of a protein and energy sup-
plement. This is discussed later in the β-hydroxyl
β-methylbutyrate (HMB) section.
Finally, recruitment in all the published trials appears
to have been difficult. Recruitment rates ranged from 4 to
9 % of the initially screened population. One author com-
ments ‘The greatest difficulty is to motivate elderly indi-
viduals to volunteer for such a study or to perform any
effort to improve their health’(11). This may introduce
bias since it may be that only particularly health con-
scious individuals will participate in the studies and
these people are not representative of older adult popula-
tions. It also illustrates the challenges faced by research-
ers in planning and funding such studies. They are likely
to be resource intensive and expensive, and it may be
necessary to conduct extensive preliminary work to es-
tablish interventions that are more attractive and accept-
able to older adults.
In summary the trials testing whole-protein sup-
plementation failed to show a consistent effect on muscle
mass, strength or function. This can be explained by the
variations in study design, composition of the protein
supplement and the failure to monitor voluntary food in-
take, adherence and baseline nutritional status. Further
large-scale clinical studies are warranted but will require
significant funding and resources.
Essential amino-acid trials
The rationale for supplementing with EAA is that they
are an anabolic stimulus for muscle synthesis(9), in par-
ticular leucine. However, there is no agreement on
what mixture of EAA may provide the best stimulus.
There are two studies which have used such a mixture
(see Table 2), providing very limited evidence that there
may be some effect on muscle mass and function through
amino-acid supplementation(22,23). The two studies used
very different EAA mixtures with the main differences
in threonine, phenylalanine and leucine, yet neither
provided a clear rationale for the mixture in use.
Furthermore, the method of delivery differed with one
study providing capsules (20/d)(22) and other asking sub-
jects to mix a powder with water or milk(23). This is par-
ticularly problematic since using milk as an optional
delivery vehicle for the EAA means that some subjects
will also receive a supplement of energy, protein (includ-
ing EAA) and other nutrients contained in the milk.
Many amino acids have a bitter taste and it remains
unclear how palatable this oral supplement was or
whether other flavours or sweeteners were used within
the powder to make its taste acceptable.
As with the whole-protein trials, these studies also suf-
fer from a lack of adherence information, no assessment
of baseline nutritional status and no assessment of volun-
tary food intake. They are also very different designs;
two arm compared with four arm study, and with and
without placebo.
Both these studies found an effect of the supplements;
one on muscle mass only(22) and the other on mass, func-
tion and strength, but only in combination with exer-
cise(23). The EAA supplement alone did not result in
significant change(23). Because of the lack of rationale
and different EAA supplements used, and the various de-
sign problems in both studies it is difficult to interpret
whether further studies into the use of EAA are war-
ranted. It may be that using HMB, a downstream metab-
olite of leucine, is a better approach, and there are five
studies exploring this option.
β-Hydroxy β-methylbutyrate trials
HMB has been shown to reduce protein degradation,
up-regulate protein synthesis and increase muscle cell
cholesterol production, leading to more stable cell mem-
branes(24,25). It is a downstream metabolite of leucine,
with approximately 5–10 % ingested leucine being con-
verted to HMB(26). This means that in order to meet
the dose of HMB generally given in trials (3 g/d)(27,28),
60 g leucine/d would have to be consumed. To obtain
this quantity of leucine through the diet would require
an individual to eat impractically large amounts (>600 g)
of high-quality protein sources (eggs, dairy and meat)
daily(29). The theory is that if only 10 % leucine is con-
verted to HMB and HMB is what makes leucine a stimu-
lator of muscle synthesis, a far larger effect could be
elicited if the rate-limiting conversion is bypassed. A
number of human studies have tested the theory of
M. Hickson4
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supplementing HMB rather than leucine,(29,30) but only
five examine outcomes relevant to sarcopenia(31–35) (see
Table 3).
There is some interesting work in ageing rats which sup-
ports the hypothesis that HMB modulates negative
age-related changes in body composition and function(36).
This group supplemented young (44 weeks) and old (86
weeks) rats with Ca-HMB for 16 weeks to produce
middle-aged (60 weeks) and very old (102 weeks) rats,
which were compared with baseline, middle-aged control
and very old control data. The results showed a leaner,
stronger body phenotype for those rats supplemented
with HMB at both middle and very old age. Animal data
are particularly useful in modelling ageing since longitudi-
nal human studies are so expensive, difficult and time-
consuming. Nevertheless, human intervention trials to
demonstrate efficacy of HMB supplementation are
required.
The results of the five studies examining sarcopenia
relevant outcomes are more consistent than either EAA
or whole protein, with three studies showing an effect
on muscle mass(31,33,35) and the other two studies show-
ing an effect for strength(32,34). The details of the studies
also show a more consistent approach. All included free-
living older adults with exclusions for major illness,
although two studies recruited from assisted living and
care facilities(32,35). All provided 2–3 g HMB/d, although
two studies included additional amino acids, arginine
and lysine, and vitamin C(32,35). The rationale for this ad-
dition was that lysine is one of the three indispensable
amino acids(37) and its requirement is potentially higher
than previously thought; thus it was added to avoid an
inadequate supply(38). Both lysine and arginine, such as
HMB, are also thought to be stimulants of muscle
protein synthesis(9,39). The format of the supplement
however varied between studies; either as capsules or a
powder, and the powder either mixed with water or
other liquid. All studies used a placebo, which appeared
adequately masked, although testing this was not done.
Only one study used an iso-energetic and iso-nitrogenous
placebo(35); the others all using what appear to be
iso-energetic placebos, although this is not clearly stated
in the papers. Adherence was generally checked through
measurement of urinary HMB, with expected increases in
urinary excretion to demonstrate adherence, and in some
studies this was backed up with logs or returned unused
capsules. Only one study rigorously controlled voluntary
dietary intake, including the protein intake to 0·8 g/kg
body weight per d(33), but this study looked specifically
at prevention of muscle loss during bed rest, rather
than muscle gain in free-living populations. A second
study monitored dietary intake with 3 d diet diaries(34).
The importance of assessing baseline nutritional
status is effectively illustrated in a re-analysis of the
Baier et al. study(35). The symptoms of vitamin D defic-
iency are known to include muscle pain and weak-
ness(40). There is some evidence that there is a vitamin
D receptor on muscle(41), and observational studies indi-
cate a positive association between vitamin D and mus-
cle function(42). A recent systematic review confirmed
that vitamin D supplementation can improve muscle
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strength, in particular in those most deficient and those
whose levels increase most(40). Thus, it is possible that
vitamin D status will influence the response to tests of
muscle strength and performance. Fuller et al.
re-analysed data to account for baseline vitamin D
status(43). They found that subjects who had a low vit-
amin D status (<30 ng 25OH-vitaminD3/ml serum)
did not respond to the HMB/Arginine/Lysine sup-
plement to the same extent as the higher status subjects
(⩾30 ng/ml). Lean mass was increased in both vitamin
D groups but muscle strength was only increased in
the high vitamin D group, suggesting a synergistic effect
of vitamin D and the supplement. Clearly, in future
studies it will be critical to assess vitamin D status at
baseline and supplement those who are insufficient.
There is one other study in bed-ridden older adults re-
ceiving artificial tube feeding for 6 months or more(44),
which also shows an effect for HMB on nitrogen ex-
cretion and body weight and body circumference. The
results are suggestive of a positive effect of HMB on mus-
cle mass but this was not measured, neither were mea-
sures of strength or function.
Overall, these data are suggestive of a beneficial effect
of HMB on older adults, but larger well-controlled stu-
dies are required that measure outcomes relevant to sar-
copenia, ideally in sarcopenic populations.
Table 3. Details of β-hydroxyl β-methylbutyrate trials to treat sarcopenia
Reference
(population)
Intervention
(duration) Dose
HMB
supplement Placebo Adherence Dietary intake Main result
Vukovich
et al.(31)
(free-living
older adults)
(a) HMB
and Ex
(b) Placebo
+ Ex (2
months)
Twelve
capsules/
d (four
caps ×
3/d)
3 g/d One
capsule: 250
mg Ca-HMB
50 mg
potassium
phosphate
Yes
Rice flour
Returned caps
every 10 d
Elevated plasma
HMB during study
period 1·69 v.
67·73 umol/l
Not controlled
but weight
stable
Muscle mass
improved for
HMB group
Flakoll et al.(32)
(free- and
assisted-living
older women)
(a) HMB,
Arg +
Lys
(b) Placebo
(No Ex)
(3
months)
One 8 oz
drink
taken at
breakfast
2 g/d Orange
drink
containing:
2 g Ca-HMB;
5 g Arg; 1·5 g
Lys HCl; 0·5 g
ascorbic acid
Yes
Same vol, same
flavour,
iso-energetic.
Maltodextrin; 0·5
g ascorbic acid ±
1·8 g non-EAA
protein
None reported Not monitored
but weight
stable
Performance
and muscle
strength
improved for
HMB group,
but not
muscle mass
Baier et al.(35)
(free- and
assisted-living
older women)
(a) HMB,
Arg +
Lys
(b) Placebo
(No Ex)
(12
months)
One
sachet/d
orange
flavoured
mixed
with water
2 or 3 g/d
depending on
body weight
>or <68 kg
2/3 g
Ca-HMB;
5/7·5 g L-Arg;
1·5/2·25 g Lys
HCl; 0·1 g
ascorbic acid
Yes
Iso-nitrogenous/
energetic. 11·8 g
non-essential
amino acids
(alanine 5·6 g,
glutamic acid 0·9
g, glycine 3·1 g,
serine 2·2 g) 0·1 g
ascorbic acid
Monthly
questionnaires
and daily
supplementation
records
Approximately 95
% over 12-month.
Urinary HMB
increased in HMB
group
Not monitored
but weight
stable or
increased
Muscle mass
improved for
HMB group
but no
changes for
strength or
function
Deutz et al.(33)
(healthy older
adults)
(a) HMB
(b) Placebo
(No Ex)
(10 d)
Two
sachets/d
mixed
with water
3 g/d One
sachet
contained:
1·5 g
Ca-HMB; 4 g
maltodextrin;
200 mg Ca;
additional
sweetener
flavouring
agents
Yes
One sachet
contained: 4 g
maltodextrin;
200 mg Ca;
additional
sweetener
flavouring agents
Urinary HMB
increased in HMB
group
Metabolically
controlled 0·8
g/kg per d
protein. Harris–
Benedict for
energy with
different
activity factors
for bed rest
Preserved
muscle mass
during bed
rest for HMB
group
Stout et al.(34)
(free-living
older adults)
(a) Placebo
(b) HMB
(c) Placebo
+ Ex
(d) HMB+
Ex (6
months)
Two
sachets/d
mixed
with
water,
milk or
juice
3 g/d one
sachet
contained:
1·5 g Ca-HMB;
4 g
carbohydrate
Yes
200 mg Ca; 4 g
carbohydrate
Urinary HMB
increased during
study, Plus logs
Dietary recall x
3 d × 3
Improved
muscle
strength for
HMB group
Ex, exercise component to the intervention; EAA, essential amino acid; HMB, β-hydroxyl β-methylbutyrate; Arg, arginine; Lys, lysine.
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Discussion of the evidence
The available evidence for protein does not allow us to
make anything more than quite tentative suppositions.
The most promising avenue does appear to be HMB
supplementation but in the context of an otherwise
adequate diet. However, the use of EAA is far from well-
investigated and further work may offer other treatment
options. It may also be that subjects with clearly defined
sarcopenia respond differently to a generally healthy
older population.
One other related issue is the timing and distribution
of the dietary protein. Some researchers have suggested
that there is a ceiling effect on the amount of protein
used for synthesis at a given meal, and suggested an
optimum protein intake of 20–30 g per meal(45,46).
Others have shown that feeding protein spread evenly
throughout meals gives greater fractional synthesis rate
compared with a skewed distribution(47), and that in free-
living older subjects protein intake can be skewed
towards a higher lunch intake, with less at breakfast
and other meals(48). However, other investigators refute
the view that there is a maximal effect of protein at a
meal, proposing a large bolus of protein should be as use-
ful as providing the same amount spread over the day(49).
Others have provided evidence that pulse feeding protein
(72–80 % provided at lunch) increases whole-body pro-
tein retention, lean muscle index (lean soft-tissue mass/
height m2) and appendicular skeletal muscle mass index
(sum of lean soft-tissue in the four limbs/height m2) com-
pared with evenly spread protein(50,51). Further research
is evidently needed to better understand how protein dis-
tribution can affect optimum health in older people.
There is also the issue of increased splanchnic amino
acid sequestration. The splanchnic bed includes the
liver, stomach, intestines, pancreas and spleen (or portal-
drained viscera). Because the portal-drained viscera
receive nutrients from dietary digestion first, their
requirements are satisfied first, potentially limiting the
availability of nutrients, including amino acids, to
peripheral tissues(52). There is some evidence that
splanchnic amino-acid sequestration is increased with
age(53), and this could potentially complicate the sup-
plementation of EAA to stimulate muscle protein syn-
thesis and protein distribution throughout the day.
Protein may be the most obvious target for a treatment
to prevent muscle loss but there are several other dietary
strategies that have been explored, but require further in-
vestigation, such as vitamin D, alcohol, dietary acid–base
load, fatty acids and antioxidants. These have all been re-
cently reviewed by Welch(7).
Recommendations for the design of future trials
Cruz-Jentoft et al. make a series of recommendations in
their review paper for the design of future nutritional stu-
dies. These include: clear well-defined populations, four
arm studies nutrition with or without exercise, standar-
dised outcome measures, attention to the timing of the
nutritional supplement particularly in respect of exercise,
and consideration of the baseline nutritional status and
frailty of the study population(10).
In addition to these recommendations I would like to
add that adherence to the nutritional intervention must
be assessed as well as its effect on voluntary food intake,
and if protein or amino acids are supplemented they are
considered in the context of the subject’s or group’s pres-
ent intake, with efforts made to improve poor intakes, as
well as including an additional supplement. This of
course is far more complex and is not as appealing as a
simple daily drink, bar or capsule, yet if we are to suc-
cessfully address the problem of sarcopenia and improve
the health of the older population, it may be that a whole
diet approach is required.
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